


CLAIMS

What is Claimed:

1. A compound having a structure of formula (I)



wherein

A is independently N or CH;

W is independently N or CH;


wherein one or both of A and W is N;
 R¹ and R² are independently a branched or a linear C₁₋₆alkyl;
 R³ is phenyl substituted by 1 or 2 R⁵ substituents;

R⁵ is independently selected from one or more halo, -OH, or NH₂;

R⁴ is halo; or


a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof.

2. The compound of claim 1 having a structure of formula (Ia)




a pharmaceutically acceptable salt thereof.


3. The compound of claim 1 wherein A is N.
4. The compound of claim 1 wherein A is CH.
5. The compound of claim 1 wherein W is N.
6. The compound of claim 1 wherein W is CH.
7. The compound of claim 1 wherein R¹ is CH₃.
8. The compound of claim 1 wherein R¹ is CH(CH₃)₂.
9. The compound of claim 1 wherein R² is CH₃.
10. The compound of claim 1 wherein R² is CH(CH₃)₂.
11. The compound of claim 1 wherein R⁵ is halo.
12. The compound of claim 11 wherein R⁵ is F.
13. The compound of claim 1 wherein R⁵ is -OH.
14. The compound of claim 1 wherein R⁵ is -NH₂.
15. The compound of claim 1 wherein R³ is




16. The compound of claim 15 wherein R³ is



17. The compound of claim 15 wherein R³ is




18. The compound of claim 15 wherein R³ is



19. The compound of claim 1 wherein R⁴ is halo.

20. The compound of claim 19 wherein R⁴ is Cl.
21. The compound of claim 19 wherein R⁴ is F.
22. A compound having a structure of formula (II)



wherein

A is independently N or CH;

W is independently N or CH;

wherein one or both A and W is N;

R¹ and R² are independently a branched or a linear C₁₋₆alkyl;


R³ is phenyl substituted by one or two R⁵ substituents;

R⁵ is independently selected from one or more halo, -OH, or NH₂; and

R⁴ is halo; or


or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof.

23. The compound of claim 22 having a structure of formula (IIa)




a stereoisomer thereof; a pharmaceutically acceptable salt thereof; a pharmaceutically acceptable salt of the stereoisomer thereof.


24. The compound of claim 22 wherein A is N.
25. The compound of claim 22 wherein A is CH.
26. The compound of claim 22 wherein W is N.
27. The compound of claim 22 wherein W is CH.
28. The compound of claim 22 wherein R¹ is CH₃.
29. The compound of claim 22 wherein R¹ is CH(CH₃)₂.
30. The compound of claim 22 wherein R² is CH₃.
31. The compound of claim 22 wherein R² is CH(CH₃)₂.
32. The compound of claim 22 wherein R⁵ is halo.
33. The compound of claim 32 wherein R⁵ is F.
34. The compound of claim 22 wherein R⁵ is -OH.
35. The compound of claim 22 wherein R⁵ is -NH₂.
36. The compound of claim 22 wherein R³ is




37. The compound of claim 36 wherein R³ is




38. The compound of claim 36 wherein R³ is












39. The compound of claim 36 wherein R³ is




40. The compound of claim 22 wherein R⁴ is halo.
41. The compound of claim 22 wherein R⁴ is Cl.
42. The compound of claim 22 wherein R⁴ is F.
43. A compound having a structure selected from:














	
	
	
	





or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof.

44. A compound having a structure selected from:










or a pharmaceutically acceptable salt.


45. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.


46. A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable excipient.


47. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.


48. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





49. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





50. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





51. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





52. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





53. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





54. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





55. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





56. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





57. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





58. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





59. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





60. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





61. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





62. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





63. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





64. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





65. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





66. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.





67. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.




68. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.



69. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.



70. The compound of claim 44 having a structure , or the pharmaceutically acceptable salt thereof.

71. A pharmaceutical composition comprising the compound of any one of claims 43, 44 or 47- 70 and a pharmaceutically acceptable excipient.

72. A method of inhibiting KRAS G12C in a cell, comprising contacting the cell with the compound of any one of claims 43, 44 or 47-70 or the pharmaceutically acceptable salt thereof.

73. A method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-44 or 47-70 or the pharmaceutically acceptable salt thereof.

74. The method of claim 73, wherein the cancer is lung cancer, pancreatic cancer, or colorectal cancer.

75. The method of any one of claims 1-44 or 47-70 or the pharmaceutically acceptable salt thereof, further comprising administering to the subject a therapeutically effective amount of an additional pharmaceutically active compound.

76. The method of claim 75, wherein the additional pharmaceutically active compound is carfilzomib.

77. The method of claim 76, wherein the additional pharmaceutically active compound is cytarabine.

78. A use of the compound according to any one of claims 1-44 or 47-70 or the pharmaceutically acceptable salt thereof for treating cancer in a subject.

79. The compound according to claim 78, wherein the cancer is a hematologic malignancy.

80. The compound according to any one of claims 1-44 or 47-70 or the pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer.

81. The compound according to claim 80, wherein the cancer is a hematologic malignancy.